Leveraging a strategy of pursuing targets undruggable by technologies other than RNAi, Dicerna Pharmaceuticals has set its sights on inking at least one industry alliance in 2009, a company official told RNAi News this week.

While “nothing is done until it’s done in this business … [discussions] are progressing very well in a very serious manner,” and Dicerna plans to have consummated its first industry partnership before the end of the year, CEO Jim Jenson said. He added that the company intends to primarily strike deals on a target-by-target basis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.